J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0091270007312903v1
48/3/303    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Google Scholar
Right arrow Articles by Kovarik, J. M.
Right arrow Articles by Schmouder, R. L.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kovarik, J. M.
Right arrow Articles by Schmouder, R. L.

PHARMACODYNAMICS

A Mechanistic Study to Assess Whether Isoproterenol Can Reverse the Negative Chronotropic Effect of Fingolimod

John M. Kovarik, PhD, FCP, Gilles-Jacques Riviere, PhD, Daniel Neddermann, PhD, Steve Maton, Thomas L. Hunt, MD and Robert L. Schmouder, MD

From Novartis Pharmaceuticals, Basel, Switzerland, and East Hanover, New Jersey (Dr Kovarik, Dr Riviere, Dr Neddermann, Mr Maton, Dr Schmouder) and PPD Development Clinics, Austin, Texas (Dr Hunt).

The sphingosine-1-phosphate receptor modulator fingolimod (FTY720) elicits a negative chronotropic effect at treatment initiation that attenuates thereafter. The authors determined whether isoproterenol can counteract this effect. In this randomized, crossover study, 14 healthy subjects received 5 infusions of isoproterenol (titrated to increase heart rate to 100-120 bpm) or intravenous placebo. The first infusion was 2 hours before and the other 4 infusions were between 3 and 6 hours after a 5-mg oral dose of fingolimod. Telemetry and pharmacokinetic data were collected for 24 hours. During isoproterenol infusion 1 (before fingolimod administration), heart rate was increased 80% from preinfusion 68 ± 9 bpm to a maximum 122 ± 15 bpm. Administration of fingolimod decreased heart rate from 73 ± 11 bpm predose to a nadir of 57 ± 8 bpm. The subsequent isoproterenol infusion 2 in the presence of fingolimod increased mean heart rate by 85% to a maximum 105 ± 21 bpm. A 41% higher total isoproterenol dose was needed to increase heart rate to the target range with fingolimod (97 ± 6 mcg) compared with isoproterenol alone (69 ± 27 mcg). Isoproterenol infusions 3 to 5 had similar effects on heart rate as infusion 2. Fingolimod had no significant influence on blood pressure responses to isoproterenol. Isoproterenol did not alter the pharmacokinetics of fingolimod. The pure beta-agonist isoproterenol can reverse the heart rate reduction that occurs transiently after initiating fingolimod treatment.

Key Words: Immunomodulators • fingolimod • isoproterenol • heart rate • drug interactions

Address for correspondence: John M. Kovarik, Novartis Pharma, Building WSJ 210.423, 4002 Basel, Switzerland; e-mail: john.kovarik{at}novartis.com.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American College of Clinical Pharmacology